drugset / Trial / NCT01238679
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study evaluates the safety and tolerability of multiple, escalating doses of PF-04958242 administered orally to healthy adult participants.This study also evaluates the plasma and urine multiple dose pharmacokinetics (PK) of PF-04958242.
Timeline
- Start
- 2010-11-24
- Primary completion
- 2011-05-03
- Completion
- 2011-05-03
Outcome
Outcome not reported
Stopped: “See termination reason in detailed description.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PESAMPATOR | Small molecule | 0.03 mg | Oral |
| Subject | PESAMPATOR | Small molecule | 0.05 mg | Oral |
| Subject | PESAMPATOR | Small molecule | 0.1 mg | Oral |
| Subject | PESAMPATOR | Small molecule | 0.15 mg | Oral |
| Subject | PESAMPATOR | Small molecule | 0.2 mg | Oral |
| Subject | PESAMPATOR | Small molecule | 0.25 mg | Oral |
Indications
No indication recorded.